Loading patent…
AssigneePGxHealth, LLC
InventorsJeroen Aerssens, Maria Athanasiou, Carlos Brain, Nadine Cohen, Bradley Dain, R. Rex Denton, Richard S. Judson, Vural Ozdemir, Carol R. Reed
Estimating the term…
Haplotypes in the CDK5 gene associated with cognitive response to galantamine treatment are disclosed. Compositions and methods for detecting and using these CDK5 haplotypes in a variety of clinical applications are disclosed. Such applications include articles of manufacture comprising galantamine or derivatives thereof that are approved for treating patients having one of these CDK5 haplotypes, methods and kits for predicting the response of an individual to galantamine based upon his/her haplotype profile, and methods for treating Alzheimer's patients based upon their haplotype profile.
-28. (canceled)
A kit for determining whether an individual has a response marker I, a response marker II, or a response marker III, the kit comprising a set of one or more oligonucleotides designed for identifying at least one of the alleles at each polymorphic site (PS) in a set of one or more PSs, wherein the set of one or more PSs comprises:
-76. (canceled)
Dependencies are inferred from the claim text.